Quest Diagnostics (DGX) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.98, $0.07 better than the analyst estimate of $1.91. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.26 billion.
GUIDANCE:
Quest Diagnostics sees FY2023 EPS of $8.40-$9.00, versus the consensus of $8.69. Quest Diagnostics sees FY2023 revenue of $8.83-9.03 billion, versus the consensus of $9.13 billion.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
- Coforge Ltd (COFORGE:IN) PT Raised to INR2,460 at UBS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
